These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 26686802)

  • 1. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
    Lloyd AJ; Kerr C; Penton J; Knerer G
    Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
    Skaltsa K; Longworth L; Ivanescu C; Phung D; Holmstrom S
    Value Health; 2014 Mar; 17(2):238-44. PubMed ID: 24636382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
    Rowen D; Young T; Brazier J; Gaugris S
    Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
    Wu EQ; Mulani P; Farrell MH; Sleep D
    Value Health; 2007; 10(5):408-14. PubMed ID: 17888106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.
    Kuppen MCP; Westgeest HM; van den Eertwegh AJM; Coenen JLLM; van Moorselaar RJA; van den Berg P; Geenen MM; Mehra N; Hendriks MP; Lampe MI; van de Luijtgaarden ACM; Peters FPJ; Roeleveld TA; Smilde TJ; de Wit R; van Oort IM; Gerritsen WR; Uyl-de Groot CA
    Clin Genitourin Cancer; 2020 Jun; 18(3):e233-e253. PubMed ID: 31883940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
    Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
    J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
    [No Abstract]   [Full Text] [Related]  

  • 10. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
    Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
    Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
    Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
    JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer.
    Bourke S; Bennett B; Oluboyede Y; Li T; Longworth L; O'Sullivan SB; Braverman J; Soare IA; Shaw JW
    Health Qual Life Outcomes; 2024 Sep; 22(1):81. PubMed ID: 39304893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
    Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
    Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.
    Diels J; Hamberg P; Ford D; Price PW; Spencer M; Dass RN
    Qual Life Res; 2015 Mar; 24(3):591-8. PubMed ID: 25326871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.
    Murasawa H; Sugiyama T; Matsuoka Y; Okabe T; Hino A; Tanaka N; Sugimoto M; Oyama M; Fujimoto K; Horie S; Noto S; Shimozuma K
    Qual Life Res; 2019 Sep; 28(9):2383-2391. PubMed ID: 31025290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
    Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
    Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
    Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
    J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.